Sodium-glucose co-transporter inhibitor dapagliflozin attenuates cognitive deficits in sporadic Alzheimer’s rat model

Ayse Nur HAZAR-YAVUZ 1,* 1, Sila YILDIZ 2 2, Rumeysa KELES KAYA 3 3, Muhammet Emin CAM 1.4,5 4, Levent KABASAKAL 1 5

1 Department of Pharmacology, Faculty of Pharmacy, Marmara University, Istanbul, Turkey.
2 Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, Scotland.
3 Department of Medical Pharmacology, Faculty of Medicine, Sakarya University, Sakarya, Turkey.
4 Department of Mechanical Engineering, University College London, London, England.
5 Centre for Nanotechnology and Biomaterials Research, Marmara University, Istanbul, Turkey.

* Corresponding Author. E-mail: ayse.hazar@marmara.edu.tr (A.N.H.Y.); Tel. +90-0216-777 52 00 (5392).

ABSTRACT: Alzheimer’s disease (AD) and Type 2 Diabetes Mellitus (T2DM) are both characterized by similar pathologies, and studies have shown that various drugs from both groups may be effective in another. The effects of sodium-glucose co-transporter (SGLT)2 inhibitors in AD are unknown. According to molecular docking studies, various SGLT inhibitors have acetylcholinesterase (AChE) inhibition activity, which is therapeutic target for AD. In this study, we investigated the effects of SGLT2 inhibitor dapagliflozin on intracerebroventricular (icv) streptozotocin (STZ) induced sporadic AD rats using open field test (OFT), novel object recognition test (NORT), passive avoidance test (PAT) and Morris’s water maze test (MWMT).

Rats were randomly divided into 4 groups: vehicle-control, icv STZ, dapagliflozin, and galantamine treatments groups. STZ was injected bilaterally in two divided doses on day 1 and 3. All treatments began on day 1 and continued to day 21. OFT was performed for evaluating animal locomotor activity and anxiety. Other behavioral tests, NORT, PAT, and MWMT was performed for determining of learning and memory ability of rats. On day 21, all rats were decapitated.

Our results showed that treatments with dapagliflozin and galantamine significantly prevented learning and memory deficits in behavioral tests. Dapagliflozin may present as a potent dual inhibitor of SGLT2 and AChE. Our results may form the basis of future dual treatment against diabetes and diabetes-related neurological diseases. The effects of possible dual AChE and SGLT2 inhibition by a single compound may help to establish new drugs that perform both anti-AD and antidiabetic action.

KEYWORDS: Dapagliflozin; Alzheimer’s disease; type 2 diabetes mellitus; sodium-glucose co-transporter inhibitor.

1. INTRODUCTION

Alzheimer’s disease (AD) is identified with increasing memory loss and other cognitive functions and it is the most observed type of dementia. AD can be categorized as late-onset sporadic AD (SAD) and early-onset familial AD (FAD). Most cases of AD are multifactorial SAD which includes several etiopathogenic mechanisms. In addition to many risk factors affecting AD; neuroinflammation, head trauma, impaired brain glucose/energy metabolism, diabetes mellitus (DM) and the presence of Apolipoprotein E (ApoE)-ε4 allele are among the risk factors for AD [1].

AD is mainly characterized by the formation of particles in senile plaques and neurofibrillar tangles (NFTs) [2]. The senile plaques consist mainly of amyloid beta (Aβ) and the NFTs consist of hyperphosphorylated tau (p-tau) proteins. It has been shown that cell loss is associated with increased impaired oxidative stress and mitochondrial dysfunction, oxidative stress, and cerebrovascular disease or cerebral hypoperfusion. In addition, it was shown that the damaged process of glucose uptake in brain and energy metabolism defects accompany the early stages of AD [3].

How to cite this article: Hazar-Yavuz AN, Yildiz S, Keles Kaya R, Cam ME, Kabasakal L. Sodium-glucose co-transporter inhibitor dapagliflozin attenuates cognitive deficits in sporadic Alzheimer’s rat model. J Res Pharm. 2022; 26(2): 298-310. http://dx.doi.org/10.29228/jrp.128
There is a rising interest in clarifying the role of insulin resistance, hyperinsulinemia, and type 2 diabetes mellitus (T2DM) in the pathogenesis of AD, cognitive impairment, and neuronal cytoskeletal lesions associated with AD and Aβ accumulation in the brain [4-5]. Increasing evidence suggests that T2DM is an independent risk factor for SAD [6-7]. In many previous studies, intracerebroventricular (icv) streptozotocin (STZ) has been used to establish an AD-type neurodegeneration model in adult mice and rats [8-11]. STZ, a glucosamine-nitrosourea derivative, causes DM by specifically destroying beta cells in the islets of the pancreas when applied to the periphery. In addition to the lack of understanding of the cytotoxicity mechanism of STZ, it is known that the alkylation properties of STZ metabolites produce reactive oxygen species, causing oxidative stress and DNA damage [12].

While STZ damages pancreatic beta cells as well as another glucose transporter (GLUT)2 expressing organs, single or double icv STZ injection(s) chronically reduces cerebral glucose uptake and produce many other effects, including molecular, pathological, and behavioral properties of AD [13]. These effects led to the use of icv STZ to form a neurodegeneration model. In adult rats, icv STZ causes a chronic decrease in glucose and glycogen metabolism (10-30%) in the brain [8]. These effects are associated with significantly reduced brain energy balance and oxidative metabolism [9], inhibition of insulin receptor function [11], and progressive deficiencies in learning, memory, cognitive behavior [11-15]. Therefore, this model provides the biochemical and physiological abnormalities that occur in AD. It has been shown that icv STZ may mimic brain insulin resistance has negative effects on cognitive function in patients with DM and AD [16].

Cholinergic system hypofunction may trigger dementia or worse in AD because it plays an important role in learning and memory processes of the central cholinergic system [17]. Acetylcholine (ACh) is essential for the functioning of cholinergic delivery to regulate and enhance learning and memory processes. Many studies with mice and rats have shown that the icv STZ model increases acetylcholinesterase (AChE) activity [18-19].

On the other hand, AD and T2DM are very similar pathologies, and several studies have shown that various drugs from both groups may be effective in another [20-27]. The effects of sodium-glucose co-transporter (SGLT)2 inhibitors, which have recently received Food and Drug Administration (FDA) approval for T2DM are unknown on AD.

Studies with dapagliflozin [28], empagliflozin [29], and canagliflozin [30], SGLT2 inhibitors, have shown that these drugs improve cognitive function. In the study investigating the cognitive efficacy of dapagliflozin, vildagliptin, and their combination; all treatments in obese rats reduced insulin sensitivity, mitochondrial ROS production, mitochondrial membrane potential change, as well as inflammation and apoptosis. Only dapagliflozin of treatments improved the deterioration of hippocampal synaptic plasticity. The improvement in the learning-memory shown in Morris’ water maze test (MWMT) has been associated with these findings [28].

Another aspect that makes SGLT inhibitors remarkable for AD was found in molecular docking studies. According to molecular docking studies, various SGLT inhibitors perform AChE inhibition as well as SGLT inhibition [31-33]. In a molecular docking study with dapagliflozin, it has been shown that the hydrophobic and cation-n interactions of dapagliflozin play an important role in the correct positioning of dapagliflozin in the catalytic site of the SGLT2 and AChE enzyme. Thus, it was reported that dapagliflozin may act as a potent dual inhibitor of SGLT2 and AChE. It is stated that the described results may form the base of future dual treatment against DM and DM-related neurological disorders [31].

The effects of SGLT2 inhibitor dapagliflozin on depression and anxiety were investigated by our team for the first time. According to this research, antidepressant [34] and anxiolytic [35] effects of dapagliflozin were found. The antidepressant effect of dapagliflozin was evaluated with the forced swim test and it was found that when dapagliflozin was administered acutely, it showed an antidepressant-like effect [34]. Anxiolytic effect was evaluated by open field test (OFT). According to this test, when dapagliflozin was administered acutely, it increased the time spent in the center and decreased the number of grooming as the anxiolytic effect [35].

As an antidiabetic SGLT2 inhibitor of dapagliflozin, it is thought to have effects on AD with its acetylcholinesterase activity due to its structural properties along with regulation glucose metabolism. In this study, we investigated the effects of dapagliflozin on AD in the icv STZ induced SAD model using novel object recognition test (NORT), passive avoidance test (PAT), and MWMT by comparing it with the galantamine which is the FDA-approved AD drug.
2. RESULTS

2.1. Effects of Dapagliflozin on Open Field Test

We used OFT to measure the locomotor activity of rats (Figure 1). There is no significant difference between groups on squares crossed in OFT. In the present study, no significant difference was found between different groups on locomotor activity. This result eliminates the probability that the locomotor activity of the rats may itself contribute to changes in cognitive tests, particularly the tasks in the MWMT.

![Figure 1. Squares crossed of rats in open field test. Values are expressed in Mean±SEM (n=8). One-way ANOVA with Tukey post-test was performed using GraphPad Prism version 6.05 for Windows. (C: Vehicle-control group, icvSTZ: intracerebroventricular Streptozotocin group, icvSTZ+D: Dapagliflozin treatment group, icvSTZ+G: Galantamine treatment group.]

2.2. Effects of Dapagliflozin on Novel Object Recognition Test

When control group was examined in the novel object recognition test, there was a significant difference (p<0.05) between the exploration time of familiar and novel object; when STZ group was examined, no significant difference was found between the exploration time of familiar and novel objects (Figure 2). Besides, the discrimination index (p<0.05) and the preference index (p<0.05) were shown to be decreased in the STZ group compared to the control group (Figure 3). These results demonstrated a short-term memory impairment in icv STZ rats.
In the treatment groups, it was seen that there is a significant difference between the exploration time of familiar and novel objects (Figure 2). Also, STZ+Dapagliflozin group (p<0.01) was found to be significantly higher than STZ+Galantamine group (p<0.05). The discrimination index increased on STZ+Dapagliflozin group compared to STZ group (p<0.05) (Figure 3a). The preferential index increased on STZ+Dapagliflozin group (p<0.01) and STZ+Galantamine group (p<0.05) compared to STZ group (Figure 3b). These results suggest that short-term memory impairment improved in the treatment groups compared to STZ group.

Figure 2. Exploration time of rats in novel object recognition test. Values are expressed in Mean±SEM (n=8). One-way ANOVA with Tukey post-test using GraphPad Prism version 6.05 for Windows. *p<0.05 in comparison with C Familiar, ++p<0.01 in comparison with icvSTZ+D Familiar, #p<0.05 in comparison with icvSTZ+G Familiar. (C: Vehicle-control group, icvSTZ: intracerebroventricular Streptozotocin group, icvSTZ+D: Dapagliflozin treatment group, icvSTZ+G: Galantamine treatment group.)

In the treatment groups, it was seen that there is a significant difference between the exploration time of familiar and novel objects (Figure 2). Also, STZ+Dapagliflozin group (p<0.01) was found to be significantly higher than STZ+Galantamine group (p<0.05). The discrimination index increased on STZ+Dapagliflozin group compared to STZ group (p<0.05) (Figure 3a). The preferential index increased on STZ+Dapagliflozin group (p<0.01) and STZ+Galantamine group (p<0.05) compared to STZ group (Figure 3b). These results suggest that short-term memory impairment improved in the treatment groups compared to STZ group.

Figure 3. Discrimination index (a) and preferential index (b) of rats in novel object recognition test. Values are expressed in Mean±SEM (n=8). One-way ANOVA with Tukey post-test was performed using GraphPad Prism version 6.05 for Windows. a: *p<0.05 in comparison with C and +p<0.05 in comparison with icvSTZ. b: *p<0.05 in comparison with C, ++p<0.01 in comparison with icvSTZ and #p<0.05 in comparison with icvSTZ. (C: Vehicle-control group, icvSTZ: intracerebroventricular Streptozotocin group, icvSTZ+D: Dapagliflozin treatment group, icvSTZ+G: Galantamine treatment group.)
3.3. Effects of Dapagliflozin on Passive Avoidance Test

In the PAT, the step-through latency time in STZ group decreased (p<0.05) when compared to control group (Figure 4). The reduced capacity in remembering to encounter electric shock following entrance into the dark compartment. When treatment groups were examined, no significant change was observed compared to STZ group.

![Figure 4. Step-through latency of rats in passive avoidance test. Values are expressed in Mean±SEM (n=8). One-way ANOVA with Tukey post-test was performed using GraphPad Prism version 6.05 for Windows. *p<0.05 in comparison with C. (C: Vehicle-control group, icvSTZ: intracerebroventricular Streptozotocin group, icvSTZ+D: Dapagliflozin treatment group, icvSTZ+G: Galantamine treatment group.)](image)

2.4. Effects of Dapagliflozin on Morris’ Water Maze Test

During the training phase, there was a decrease in latency to find the platform underwater in all rats, this result shows that all rats learned the platform. However, it was observed that icvSTZ group needs more time for training. These results indicate that there is a deterioration in the coding and remembering of the spatial memory (Figure 5).

![Figure 5. Latency to platform of rats in Morris’ water maze test. Values are expressed in Mean±SEM (n=8). One-way ANOVA with Tukey post-test was performed using GraphPad Prism version 6.05 for Windows.](image)
3. DISCUSSION

SAD is a late-onset disease and usually develops after the age of 65 years [14]. The insulin-resistant brain condition with anomalies in glucose/energy metabolism and abnormal signaling in insulin plays a central role in neurodegeneration in SAD [3]. The icv STZ rat model has been proposed to produce cognitive deficits similar to those seen in SAD [36]. Therefore, in our study, the icv STZ rat model was used to mimic SAD. The phenotypes of icv STZ rats associated with DM and brain insulin resistance were shown to be at high risk for the development of AD-like pathology and cognitive decline [37].

In most studies, the effects of icv STZ on brain function and behavior were observed in relatively short period of time, such as several weeks [13]. In one of the most recent reviews [38], the cognitive and neurochemical changes triggered by icv STZ injection follow a three-stage time-dependent model: acute response develops within the first 1 month; there is a tendency to return to normal values within 1 to 3 months; and finally, in 6 to 9 months, the decompensation phase takes place slowly and gradually. On the basis of all these, we preferred the model with two times icv STZ administration on day 1 and 3 of the study which will last for 21 days.

NORT is a cognitive test that estimates non-spatial visual episodic memory and is based on the behavior of rodents in discovering objects [39]. In our study, as shown in previous studies, it has been shown that icv STZ administration disrupts learning and memory in exploratory activity, discrimination index and preferential index in NORT. Our treatment groups, dapagliflozin and galantamine, enhanced this deterioration.

Rats, naturally prefer dark places to bright places, and this preference is changed with a single conditioning session in the PAT [40]. Many previous studies have found that the step-through latency time associated with learning-memory is reduced in the PAT [41-42]. In our study, icv STZ was also found to reduce latency time. However, no significant difference was found in the treatment groups compared to icv STZ group.

MWMT, one of the common tests to assess the cognitive function of rodents in behavioral studies, was used in this study as a model for assessing spatial learning and memory [43]. The inability of the rats to learn the platform in the labyrinth in this test shows that they cannot remember and encode spatial information which is a characteristic of cognitive failure due to brain disruption [3]. Some brain regions and neurotransmitter systems such as the hippocampus, striatum, basal forebrain, brain cortex, and cerebellum have been shown to play an important role in the MWMT performance of rodents [39, 43]. Moreover, avoiding water in the maze serves as a motivation for the test and is advantageous as it eliminates the use of other motivational stimuli such as food and water deprivation. Additionally, water provides a homogeneous environment and defeats interference from odorous cues [43]. In the present study, a significant decrease in the learning time during the 4 training days in the control group indicated that normal memory results were obtained, while the increase in the time spent on the target quadrant to investigate the platform removed during the probe test indicates that the memory is normal [14]. Different studies have shown that icv STZ causes cognitive impairment in the rodent MWMT [44-48]. In our study, icv STZ caused the time to reach the platform to be higher than other groups and increased the time to reach the target quadrant and decreased the time spent on the target quadrant. These findings show that icv STZ causes memory impairment. When the treatment groups are examined, it is seen that the time to reach the platform is shorter on training days, the time it takes to reach the target quadrant on the probe test is shortened and the total time spent on the target quadrant increases. In our study, we demonstrated that the devastating effect of icv STZ on acquisition learning was reversed by dapagliflozin. These results indicate that treatment with dapagliflozin may prevent memory loss in the brain of rats exposed to STZ-induced cognitive failure.

AChE inhibition is the main target for AD treatment [49]. AChE is also known to play a role in human neocortical neuroplasticity processes [50]. There is some critical structural and functional confirmation associating AChE to AD: a part near the C-terminus in the AChE structure is poorly similar to the N-terminus of the Aβ peptide [51]. In a comparative study on neurotoxicity, AChE complexed human Aβ peptide fibrils
showed greater toxicity than uncomplexed Aβ peptide fibrils. AChE can increase both amyloid deposition and toxicity of this deposition [52].

Most AD studies have focused on the expression of choline acetyltransferase (ChAT), a synthase enzyme for ACh, and AChE because ACh levels and energy metabolism are reduced in early AD. Rats treated with icv STZ also show decreased levels of AChE. Increased levels of AChE expression in the icv STZ brain may cause an increase in ACh, thereby exacerbating ACh deficiencies caused by a decrease in ChAT expression. Since AChE is expressed in many cell types, including glia, the significantly increased astrocyte population in icv STZ brains may result in increased expression of AChE in this model. It is also interesting to find reduced ChAT expression in the icv STZ model because insulin stimulates ChAT, ChAT regulates Ach biosynthesis, and icv STZ disrupts insulin signals in the central nervous system [12].

Many studies have shown that icv STZ causes cognitive deficits in rodents identified using behavioral and biochemical analyses. In these tests, it was observed that icv STZ administration increased AChE level activity. Furthermore, in rats icv-STZ reduces the synthesis of acetyl-coenzyme A (acetyl-CoA) and consequently causes the cholinergic system has an important role in the learning and memory process, so hypofunction of cholinergic system may trigger memory loss and confusion in Alzheimer’s disease, or may be worse [53]. It has been reported that cholinomimetic drugs such as donepezil improve memory deficiency and anticholinergic drugs such as scopolamine cause amnesia in animals [54-55]. ACh is essential for the proper functioning of cholinergic delivery to balance and develop learning and memory processes. The synthesis of ACh depends on the presence of acetyl-CoA and insulin, which regulate the activity of ChAT [18].

Inhibition of SGLT2 serves as a novel approach to diminish hyperglycemia independent of insulin secretion or effect and also demonstrates a new pharmacotherapy for the treatment of T2DM [56-57]. SGLT2 is one of the best targets in the treatment of DM. AChE has long been considering a therapeutic target for AD. Thus, dapagliflozin may present as a potent dual inhibitor of SGLT2 and AChE. The results expressed may form the basis for future dual treatment against DM-related neurological diseases. The effects of possible dual AChE and SGLT2 inhibition by a single compound may help to establish new drugs that display both anti-AD and antidiabetic action. Dapagliflozin can represent as a dual inhibitor for AChE and SGLT2. Importantly, since the development of DM is associated with AD, the design of new AChE inhibitors based on antidiabetic drug scaffolds would be particularly useful. It is estimated that dapagliflozin may be an effective dual inhibitor of AChE and SGLT2. Both hydrophobic and cation-n interactions play an equally important role in the correct positioning of dapagliflozin with AChE and SGLT2 to allow the basis of a future dual treatment against DM-related neurological disease [31].

In a study [28], the effect of dapagliflozin on peripheral insulin sensitivity, brain insulin sensitivity, hippocampal synaptic plasticity, brain mitochondrial function, brain inflammation, brain apoptosis and cognitive function in the obese-insulin resistant state were investigated. According to the results of this study, the possible mechanisms underlying dapagliflozin in the recovery of cognitive function in high fat diet-induced obese rats are to restore peripheral insulin sensitivity, to substantially reduce brain oxidative stress, to improve brain mitochondrial function, and to restore brain inflammation; in addition to insulin signaling has been shown to reduce brain apoptosis leading to increased brain insulin sensitivity and hippocampal synaptic plasticity.

In an animal study with another SGLT2 inhibitor, canagliflozin, it was shown that canagliflozin improves memory-impaired function by affecting cholinergic and monoaminergic systems in the scopolamine-induced amnesia model [30]. In this study, it was also found that canagliflozin reduces cerebral AChE activity in obese diabetic rats.

In a study performed with empagliflozin, it was found that empagliflozin reduced cerebral oxidative stress DNA oxidative damage in db/db mice. In the same study, it has been shown that empagliflozin increases cerebral brain-derived neurotrophic factor (BDNF) level and it is thought that empagliflozin increases BDNF and improves oxidative stress, which is responsible for improving cognitive damage [29].

The reversal of STZ dementia with dapagliflozin may be due to the AChE inhibitory and neuroprotective effect of dapagliflozin, which maintains ACh levels in the synaptic cleft. Based on our behavioral results, it can be said that the proposed interaction with molecular modeling for the dapagliflozin compound is in full agreement with the experimental affinity and is similar to a classical anticholinesterase such as clinically used galantamine.
4. CONCLUSION

According to our results, treatments with dapagliflozin and galantamine significantly prevented learning and memory deficits in behavioral tests. Dapagliflozin may present as a potent dual inhibitor of SGLT2 and AChE. Thus, the improvement in cognition is probably due to the effects of dapagliflozin on SGLT2 inhibition, as well as inhibition of AChE and its effect on neuronal plasticity and oxidative stress. It is important to clarify the mechanism of these effects in future studies.

5. MATERIALS AND METHODS

5.1. Chemicals

STZ was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Dapagliflozin and galantamine were purchased from Sigma-Aldrich, Inc. (St. Louis, Missouri, USA).

5.2. Animals

All animal experiments were carried out with the approval of Marmara University Animal Experiments Local Ethics Committee (permission number: 38.2018.mar). Thirty-two adult female and male Wistar albino rats (250-350 g) (n=8 in each group) were obtained from Marmara University The Experimental Animal Implementation and Research Center. The rats were housed under controlled temperature (20±2 °C), in humidity (40-60 %) and light (12 h/12 h light/dark regime)-regulated rooms. The animals were kept on a standard rodent pellet diet, with tap water available ad libitum. All rats were kept in their cages for a one-week study to adapt conditions before starting the experiment.

5.3. Experimental Design of Study

The experimental design of study is shown in Figure 6. Rats were randomly divided into 4 groups:
- Vehicle-control group (C; healthy rats were given bilaterally icv citrate buffer in 5 µl volume on day 1 and 3 of study and intragastric distilled water on each day),
- icv STZ group (icvSTZ; Alzheimer rats were given bilaterally icv 3 mg/kg STZ with citrate buffer in 5 µl volume on day 1 and 3 of study and intragastric distilled water on each day),
- Dapagliflozin treatment group (icvSTZ+D; Alzheimer rats treated with dapagliflozin were given bilaterally icv 3 mg/kg STZ with citrate buffer in 5 µl volume on day 1 and 3 of study and intragastric 1 mg/kg Dapagliflozin [28] with distilled water on each day) and
- Galantamine treatment group (icvSTZ+G, positive control group; Alzheimer rats treated with 10 mg/kg galantamine were given bilaterally icv 3 mg/kg STZ with citrate buffer in 5 µl volume on day 1 and 3 of study and intragastric 10 mg/kg galantamine [27] with distilled water on each day).

All treatments began on day 1 of the experiment and continued to day 21. On day 21, the last day of study, all rats were decapitated.

5.4. Induction of Alzheimer: Intracerebroventricular Injection of STZ

Rats were anesthetized with ketamine hydrochloride (100 mg/kg, i.p.; Pfizer) and xylazine hydrochloride (10 mg/kg, i.p.; Bayer). The scalp was shaved, cleaned and cut to reveal the skull. The rat was placed in the stereotaxic frame and a midline sagittal incision was made in the scalp. On both sides of the skull, holes were drilled using the following coordinates: 0.8 mm posterior to bregma, 1.5 mm lateral to sagittal suture and 3.6 mm beneath on brain surface. STZ (1.5 mg/kg of each hole, totally 3 mg/kg of each day) was injected bilaterally in two divided doses on days 1 and 3. The concentration of STZ in citrate buffer was adjusted to give a total of 3 µl of the solution to both holes. C animals received icv injection of the same volume.
of citrate buffer on days 1 and 3. After the second injection, the skin was sutured and then daily antiseptic powder was applied [58-59].

5.5. Behavioral Tests

5.5.1. Open Field Test

OFT is one of the most accepted procedures for evaluating animal locomotor activity [60]. On day 13 of the study, the animals were put to OFT. OFT apparatus which rats have previously unknown consisted of square based Plexiglas box (50 x 50 bases, 40 cm high) and open from above. The ground is divided into 25 equal squares, each 10 x 10 cm and consisted of two regions: the peripheral region (10 cm from each wall in the area) and the central region. Each animal was placed and evaluated separately on the apparatus. The animals’ behavior was recorded on video for 5 minutes and evaluated the number of squares passed by two researchers as double-blind. The number of squares passed was considered a measure of locomotor activity. The apparatus surfaces were cleaned with consecutive trials to eliminate any bias that might have occurred due to the odor of the previous rat [41].

5.5.2. Novel Object Recognition Test

We used the NORT to examine short-term memory. NORT is a relatively rapid behavioral test that can be used as a pre-screen. NORT’s simple design utilizes the spontaneous behavior of rats to approach and discover novel objects with a naturally activating stimulus. When spontaneous behavior is examined, artificial stimulus, food deprivation, reinforcement and/or prior training are not required. NORT was performed in a 40 cm high walled black plexiglass open area (50 x 50 cm) at dimly lit condition on day 14 (habituation) and 15 (test). Rats were habituated to the NORT area without any object to acclimate to the environment for 30 minutes 24 hours before testing. In this test, object recognition was performed between the training phase and the test phase at 1-hour intervals. During the first trial, two identical objects were located in opposite corners and these objects are now called familiar (F). In the second trial, one of the objects was replaced by a novel (N) one. The sizes of identical and novel objects were comparable to each other. After each rat, the NORT apparatus should be cleaned with 70 % ethanol to remove any urine or scent cues. Exploration of identical and novel objects was defined if rats licked, sniffed or touched the object. Based on the exploration time of each object, the discrimination index [(N-F)/(N+F)] and preferential index [N/(N+F)] was calculated. Exploration time was scored by treatments blind researcher [39, 61].

5.5.3. Passive Avoidance Test

On days 16 and 17 were applied to acquisition and test of PAT, respectively. PAT is a fear-motivating test to examine long and short-term memories in a relational manner. In the test, the animal must behave in opposition to the innate darkness of the animal with the fear of being taught. The passage time of rats to the dark compartment was measured. In the test, a cut-off time was determined as 300 seconds if the animal did not cross to the dark compartment. The duration of the experiment is 300 seconds; if the rats do not pass into the dark compartment within 300 seconds, the experiment is terminated and the transition time is recorded as 300 seconds. The test apparatus consists of two compartments isolated with a retractable lid. One of the compartments is illuminated by a bright light, the other compartment has covered by dark opaque walls. The ground in both compartments is made of metal shocking grids. On the dark compartment, the ground is wired for 3 seconds to receive an electric shock of 0.5 mA.

On acquisition day, the rat was left in the bright compartment when the retractable lid between the compartments was closed. After rat passed into the dark compartment, the lid was closed and 0.5 mA electric shock was supplied. After the shock was given, the rat returned to the cage for the test session. On test day, the test trial was performed just like the previous day, but no foot shock was applied. In the test, a cut-off time was determined as 300 seconds if the animal did not cross to the dark compartment. After each rat, both compartments should be cleaned with 70 % ethanol [41].

5.5.4. Morris’ Water Maze Test

We used MWMT to investigate spatial learning. MWMT consist of two parts; training was performed on day 18-21. MWMT apparatus consisted of a round stainless-steel tank. The tank is divided into 4 quarters with 4 fixed points around it and there are different shapes and colors 4 cues attached to the opposite of each direction. The tank contained the escape platform of the same color as the rest of the maze (to eliminate any false positives due to vision) in the middle of one of the quarters of the area during the training. In the trials, rats were released to water their faces rotate the wall from one of the directions and allowed 75 s for finding
the platform. If the rat did not find the escape platform within 75 s, it was lightly directed to the platform and allow to remain on it for 20 s. After 1 minute, rats were released to water another direction. Therefore, all rats were trained 16 times in 4 days, 4 different directions each day. The direction order was changed every day. Rats were subjected to learning, which was evaluated for reaching the platform [39, 41].

5.6. Statistical Analysis

The results of the tests were analyzed by one-way ANOVA and two-way ANOVA followed by the Tukey method as a post-test and represented as mean ± standard error of the mean (S.E.M). P values < 0.05 were considered significant. Data analysis was performed using GraphPad Prism 6.5 software (San Diego, USA).

Acknowledgements: This study was financially supported by Marmara University, Scientific Research Projects Committee (Project number: SAG-C-DRP-110718-0445).

Author contributions: Concept – A.N.H.Y., M.E.C., L.K.; Design – A.N.H.Y., M.E.C., L.K.; Supervision – A.N.H.Y., M.E.C., L.K.; Resources – A.N.H.Y., S.Y. R.K.K.; Materials – A.N.H.Y., S.Y., M.E.C.; Data Collection and/or Processing – A.N.H.Y., R.K.K., M.E.C.; Analysis and/or Interpretation – A.N.H.Y., M.E.C., L.K.; Literature Search – A.N.H.Y., S.Y., R.K.K.; Writing – A.N.H.Y., S.Y., R.K.K.; Critical Reviews – A.N.H.Y., S.Y., R.K.K., M.E.C., L.K.

Conflict of interest statement: The authors declared no conflict of interest.

REFERENCES

[1] Iqbal K, Grundke-Iqbal I. Alzheimer’s disease, a multifactorial disorder seeking multitherapies. Alzheimers Dement. 2010; 6(5): 420-424. [CrossRef]
[2] Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA. 1986; 83(13): 4914-4917. [CrossRef]
[3] Chen Y, Liang Z, Blanchard J, Dai CL, Sun S, Lee MH, Grundke-Iqbal I, Iqbal K, Liu F, Gong CX. A non-transgenic mouse model (icv-STZ mouse) of Alzheimer’s disease: similarities to and differences from the transgenic model (3xTg-AD mouse). Mol Neurobiol. 2013; 47(2): 711-725. [CrossRef]
[4] Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J PharmacoL 2004; 490(1-3): 115-125. [CrossRef]
[5] Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, Kondo T, Alber J, Galldiks N, Küstermann E, Arndt S, Jacobs AH, Krone W, Kahn CR, Bruning JC. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci USA. 2004; 101(9): 3100-3105. [CrossRef]
[6] Bucht G, Adolfsson R, Lithner F, Winblad B. Changes in blood glucose and insulin secretion in patients with senile dementia of Alzheimer type. Acta Med Scand. 1983; 213(5): 387-392. [CrossRef]
[7] Cai Z, Yan LJ, Li K, Quazi SH, Zhao B. Roles of AMP-activated protein kinase in Alzheimer’s disease. Neuromolecular Med. 2012; 14(1): 1-14. [CrossRef]
[8] Plaschke K, Hoyer S. Action of the diabetogenic drug streptozotocin on glycolytic and glycogenolytic metabolism in adult rat brain cortex and hippocampus. Int J Dev Neurosci. 1993; 11(4): 477-483. [CrossRef]
[9] Duelli R, Schröck H, Kuschinsky W, Hoyer S. Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats. Int J Dev Neurosci. 1994; 12(8): 737-743. [CrossRef]
[10] Hoyer S, Muller D, Plaschke K. Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism. J Neurotransm Suppl. 1994; 44: 259-268. [CrossRef]
[11] Hoyer S, Lee SK, Löffler T, Schliebs R. Inhibition of the neuronal insulin receptor. An in vivo model for sporadic Alzheimer disease? Ann N Y Acad Sci. 2000; 920: 256-258. [CrossRef]
[12] Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer’s disease. J Alzheimers Dis. 2006; 9(1): 13-33. [CrossRef]
[13] Griep P. Intracerebroventricular streptozotocin injections as a model of Alzheimer’s disease: in search of a relevant mechanism. Mol Neurobiol. 2016; 53(3): 1741-1752. [CrossRef]
[14] Lannert H, Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci. 1998; 112(5): 1199-1208. [CrossRef]
[15] Mythili MD, Vyas R, Akila G, Gunasekaran S. Effect of streptozotocin on the ultrastructure of rat pancreatic islets. Microsc Res Tech. 2004; 63(5): 274-281. [CrossRef]

[16] Kapogiannis D, Mattson MP. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. Lancet Neurol. 2011; 10(2): 187-198. [CrossRef]

[17] Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, Khachaturian AS, Vergallo A, Cavedo E, Snyder PJ, Khachaturian ZS. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain. 2018; 141(7): 1917-1933. [CrossRef]

[18] Thome GR, Oliveira VA, Chitolina Schetinger MR, Saraiva RA, Souza D, Dorneles Rodrigues OE, Teixeria Rocha JB, Ineu RP, Pereira ME. Selenothymidine protects against biochemical and behavioral alterations induced by ICV-STZ model of dementia in mice. Chem Biol Interact. 2018; 294: 135-143. [CrossRef]

[19] Bokare AM, Bhonde M, Goel R, Nayak Y. 5-HT6 receptor agonist and antagonist modulates ICV-STZ-induced memory impairment in rats. Psychopharmacology. 2018; 235(5): 1557-1570. [CrossRef]

[20] DiTacchio KA, Heinemann SF, Dziewczapolski G. Metformin treatment alters memory function in a mouse model of Alzheimer's disease. J Alzheimers Dis. 2015; 44(1): 43-48. [CrossRef]

[21] Yin QQ, Pei JJ, Xu S, Luo DZ, Dong SQ, Sun MH, You L, Sun ZJ, Liu XP. Pioglitazone improves cognitive function via increasing insulin sensitivity and strengthening antioxidant defense system in fructose-drinking insulin resistance rats. PLoS One. 2013; 8(3): e59313. [CrossRef]

[22] Prakash A, Kumar A, Ming LC, Mani V, Majeed AB. Modulation of the Nitrergic Pathway via Activation of PPAR-gamma Contributes to the Neuroprotective Effect of Pioglitazone Against Streptozotocin-Induced Memory Dysfunction. J Mol Neurosci. 2015; 56(3): 739-750. [CrossRef]

[23] Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc. 2009; 57(1): 177-179. [CrossRef]

[24] Claxton A, Baker LD, Hanson A, Trittschu Eh, Cholerton B, Morgan A, Callaghan M, Arbuckle M, Behl C, Craft S. Long acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. J Alzheimers Dis. 2015; 45(4): 1269-1270. [CrossRef]

[25] McClean PL, Jalewa J, Holscher C. Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice. Behav Brain Res. 2015; 293: 96-106. [CrossRef]

[26] Hansen HH, Barkholt P, Fabricius K, Jelsing J, Terwel D, Pyke C, Knudsen LB, Vrang N. The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy. Brain Res. 2016; 1634: 158-193. [CrossRef]

[27] Ali MA, El-Abhar HS, Kamel MA, Attia AS. Antidiabetic effect of galantamine: novel effect for a known centrally acting drug. PLoS One. 2015; 10(8): e0134648. [CrossRef]

[28] Sa-Nguanmoo P, Tanajak P, Kerdphoo S, Jaiwongkam T, Pratchayasakul W, Chattipakorn N, Chattipakorn SC. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. Toxicol Appl Pharmacol. 2017; 333: 43-50. [CrossRef]

[29] Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma M, Nakagawa T, Kusaka H, Kim H, Sato T, Kiuchi A, Sakurai H, Iwamoto T. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc. 2010; 58(11): 2029-2035. [CrossRef]

[30] Ali MA, El-Abhar HS, Kamel MA, Attia AS. Antidiabetic effect of galantamine: novel effect for a known centrally acting drug. PLoS One. 2015; 10(8): e0134648. [CrossRef]

[31] Yavuz AN, Keles R, Ertas B, Kabasakal et al. Antidiabetic effect of galantamine: novel effect for a known centrally acting drug. PLoS One. 2015; 10(8): e0134648. [CrossRef]

[32] Yavuz AN, Keles R, Ertas B, Kabasakal et al. Antidiabetic effect of galantamine: novel effect for a known centrally acting drug. PLoS One. 2015; 10(8): e0134648. [CrossRef]

[33] Yavuz AN, Keles R, Ertas B, Kabasakal et al. Antidiabetic effect of galantamine: novel effect for a known centrally acting drug. PLoS One. 2015; 10(8): e0134648. [CrossRef]

[34] Cam ME, Yildiz S, Hazar-Yavuz AN, Keles R, Ertas B, Kabasakal L. Dapagliflozin attenuates depressive-like behavior of male rats in the forced swim test. Eur J Pharmacol. 2019; 29: 262-263. [CrossRef]
[35] Keles R, Hazar-Yavuz AN, Yildiz S, Cam ME, Sener G. Dapagliflozin attenuates anxiolytic-like behavior of rats in open field test. Eur J Pharmacol. 2019; 29: 201-202. [CrossRef]

[36] Du LL, Chai DM, Zhao LN, Li YH, Zhang FC, Zhang HB, Liu LB, Wu K, Liu R, Wang JZ, Zhou XW. AMPK activation ameliorates Alzheimer's disease-like pathology and spatial memory impairment in a streptozotocin-induced Alzheimer's disease model in rats. J Alzheimers Dis. 2015; 43(3): 775-784. [CrossRef]

[37] Du LL, Xie JZ, Cheng XS, Li XI, Kong FL, Jiang X, Ma ZW, Wang JZ, Chen C, Zhou XW. Activation of sirtuin 1 attenuates cerebral ventricular streptozotocin-induced tau hyperphosphorylation and cognitive injuries in rat hippocampi. Age. 2014; 36(2): 613-623. [CrossRef]

[38] Salkovic-Petrisic M, Knezovic A, Hoyer S, Riederer P. What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research. J Neural Transm. 2013; 120(1): 233-252. [CrossRef]

[39] Unal G, Aricioglu F. A-582941, cholinergic alpha 7 nicotinic receptor agonist, improved cognitive and negative symptoms of the sub-chronic MK-801 model of schizophrenia in rats. Psychiatr Clin Psychopharmacol. 2018; 28(1): 4-13. [CrossRef]

[40] Fujisaki Y, Matsuo R. Context-dependent passive avoidance learning in the terrestrial slug limax. Zoolog Sci. 2017; 34(6): 532-537. [CrossRef]

[41] Abdel-Aal RA, Assi AA, Kostandy BB. Rivastigmine reverses aluminum-induced behavioral changes in rats. Eur J Pharmacol. 2011; 659(2-3): 169-176. [CrossRef]

[42] Sohanaki H, Baluchnejadmojarad T, Nikbakht F, Roghani M. Pelargonidin improves passive avoidance task performance in a rat amyloid beta 25-35 model of Alzheimer's disease via estrogen receptor independent pathways. Acta Med Iran. 2016; 54(4): 245-250. [CrossRef]

[43] Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984; 11(1): 47-60. [CrossRef]

[44] D'Hoooge R, De Deyn PP. Applications of the Morris water maze in the study of learning and memory. Brain Res Brain Res Rev. 2001; 36(1): 60-90. [CrossRef]

[45] Shi L, Zhang Z, Li L, Hölscber C. A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv stz rat model. Behav Brain Res. 2017; 1(327): 65-74. [CrossRef]

[46] Kumar M, Kaur D, Bansal N. Caffeic acid phenethyl ester (CAPE) prevents development of STZ-ICV induced dementia in rats. Pharmacogn Mag. 2017; 13(1): 10-15. [CrossRef]

[47] Rajasekar N, Nath C, Hanif K, Shukla R. Intranasal insulin improves cerebral blood flow, nrf-2 expression and BDNF in STZ (ICV)-induced memory impaired rats. Life Sci. 2017; 173: 1-10. [CrossRef]

[48] Agrawal R, Mishra B, Tyagi E, Nath C, Shukla R. Effect of curcumin on brain insulin receptors and memory functions in STZ (ICV) induced dementia model of rats. Pharmacol Res. 2010; 61(3): 247-252. [CrossRef]

[49] Grifman M, Galyam N, Seidman S, Soreq H. Functional redundancy of acetylcholinesterase and neuregulin in mammalian neurogenesis. Proc Natl Acad Sci USA. 1998; 95(23): 13935-13940. [CrossRef]

[50] Garcia RR, Montiel JF, Villalon AU, Gatica MA, Aboitiz F. AChE-rich magnopyramidal neurons have a left-right size asymmetry in Broca’s area. Brain Res. 2004; 1026(2): 313-316. [CrossRef]

[51] Cottingham MG, Hollinshead MS, Vaux DJ. Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer’s amyloid-beta peptide. Biochemistry. 2002; 41(46): 13539-13547. [CrossRef]

[52] Reyes AE, Chacon MA, Dinamarca MC, Cerpa W, Morgan C, Inestrosa NC. Acetylcholinesterase-Abeta complexes are more toxic than Abeta fibrils in rat hippocampus: effect on rat beta-amyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss. Am J Pathol. 2004; 164(6): 2163-2174. [CrossRef]

[53] Dhingra D, Parle M, Kulkarni SK. Effect of combination of insulin with dextrose, D(-) fructose and diet on learning and memory in mice. Indian J Pharmacol. 2003; 35: 151-156.

[54] Sharma B, Singh N, Singh M. Modulation of celecoxib- and streptozotocin-induced experimental dementia of Alzheimer’s disease by pitavastatin and donepezil. J Psychopharmacol. 2008; 22(2): 162-171. [CrossRef]

[55] Itoh J, Nabeshima T, Kameyama T. Utility of an elevated plus-maze for the evaluation of memory in mice: effects of nootropics, scopalamine and electroconvulsive shock. Psychopharmacology. 1990; 101(1): 27-33. [CrossRef]
[56] Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009; 85(5): 520-526. [CrossRef]

[57] List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009; 32(4): 650-657. [CrossRef]

[58] Sachdeva AK, Misra S, Pal Kaur I, Chopra K. Neuroprotective potential of sesamol and its loaded solid lipid nanoparticles in ICV-STZ-induced cognitive deficits: Behavioral and biochemical evidence. Eur J Pharmacol. 2015; 747(15): 132-140. [CrossRef]

[59] Gutierres JM, Carvalho FB, Schetinger MR, Marisco P, Agostinho Morsch VM, Mazzanti CM, Bogo M, Bonan CD, Spanevello R. Anthocyanins restore behavioral and biochemical changes caused by streptozotocin-induced sporadic dementia of Alzheimer’s type. Life Sci. 2014; 96(1-2): 7-17. [CrossRef]

[60] Kraeuter AK, Guest PC, Sarnyai Z. The open field test for measuring locomotor activity and anxiety-like behavior. Methods Mol Biol. 2019; 1916: 99-103. [CrossRef]

[61] Bevins RA, Besheer J. Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study ‘recognition memory’. Nat Protoc. 2006; 1(3): 1306-1311. [CrossRef]